PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein - PubMed
. 2009 Nov;35(5):1015-23.
doi: 10.3892/ijo_00000416.
Affiliations
- PMID: 19787255
- DOI: 10.3892/ijo_00000416
PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein
Yayun Liang et al. Int J Oncol. 2009 Nov.
Abstract
Mutation of the p53 tumor suppressor gene is a common event in many types of tumors, including breast cancers. Mutant p53 (mtp53) protein is thought to promote tumor cell survival and resistance to chemotherapeutic drugs. Therefore, restoring p53 function by converting existing mtp53 to the wild-type p53 (wtp53) conformation is being pursued as one strategy to promote apoptosis of tumor cells. PRIMA-1 (p53 re-activation and induction of massive apoptosis) is a non-toxic small molecule that converts mtp53 to the active conformation and induces apoptosis in tumor cells. Here we examined whether PRIMA-1 activates mtp53 and induces cell death in vitro and in vivo in estrogen-responsive breast cancer cell lines that express mtp53 (BT-474, HCC-1428, and T47-D). Fluorescent staining with conformation-specific p53 antibodies demonstrated that PRIMA-1 converted mtp53 into the wtp53 conformation. In vitro treatment of tumor cells with PRIMA-1 (0-50 microM) led to a dose-dependent loss of cell viability and induced cell death markers. In contrast, PRIMA-1 had no effect on the viability of MCF-7 cells, normal breast cells, and endothelial cells, all of which express wtp53 protein. PRIMA-1 treatment of mice inhibited the growth of tumors from xenografts of BT-474, HCC-1428, and T47-D cells but did not influence xenografts obtained from MCF-7 cells. Mechanistic studies showed that PRIMA-1 induced the mitochondrial-dependent apoptotic pathway in mtp53-expressing breast cancer cells. Our findings suggest that PRIMA-1 renews the susceptibility of mtp53-expressing breast tumors to apoptosis and should be investigated for use in breast cancer therapy.
Similar articles
-
Liang Y, Besch-Williford C, Benakanakere I, Hyder SM. Liang Y, et al. Int J Oncol. 2007 Oct;31(4):777-84. Int J Oncol. 2007. PMID: 17786308
-
Liang Y, Besch-Williford C, Benakanakere I, Thorpe PE, Hyder SM. Liang Y, et al. Breast Cancer Res Treat. 2011 Jan;125(2):407-20. doi: 10.1007/s10549-010-0851-x. Epub 2010 Mar 27. Breast Cancer Res Treat. 2011. PMID: 20349129 Free PMC article.
-
Benakanakere I, Besch-Williford C, Ellersieck MR, Hyder SM. Benakanakere I, et al. Endocr Relat Cancer. 2009 Mar;16(1):85-98. doi: 10.1677/ERC-08-0069. Epub 2008 Dec 15. Endocr Relat Cancer. 2009. PMID: 19075036
-
Menichini P, Monti P, Speciale A, Cutrona G, Matis S, Fais F, Taiana E, Neri A, Bomben R, Gentile M, Gattei V, Ferrarini M, Morabito F, Fronza G. Menichini P, et al. Cells. 2021 Jan 7;10(1):98. doi: 10.3390/cells10010098. Cells. 2021. PMID: 33430525 Free PMC article. Review.
-
Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.
Wiman KG. Wiman KG. Oncogene. 2010 Jul 29;29(30):4245-52. doi: 10.1038/onc.2010.188. Epub 2010 May 24. Oncogene. 2010. PMID: 20498645 Review.
Cited by
-
Teoh PJ, Bi C, Sintosebastian C, Tay LS, Fonseca R, Chng WJ. Teoh PJ, et al. Oncotarget. 2016 Sep 20;7(38):61806-61819. doi: 10.18632/oncotarget.11241. Oncotarget. 2016. PMID: 27533450 Free PMC article.
-
Evaluation of a Covalent Library of Diverse Warheads (CovLib) Binding to JNK3, USP7, or p53.
Klett T, Schwer M, Ernst LN, Engelhardt MU, Jaag SJ, Masberg B, Knappe C, Lämmerhofer M, Gehringer M, Boeckler FM. Klett T, et al. Drug Des Devel Ther. 2024 Jul 1;18:2653-2679. doi: 10.2147/DDDT.S466829. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 38974119 Free PMC article.
-
Precision medicine in gastric cancer.
Bonelli P, Borrelli A, Tuccillo FM, Silvestro L, Palaia R, Buonaguro FM. Bonelli P, et al. World J Gastrointest Oncol. 2019 Oct 15;11(10):804-829. doi: 10.4251/wjgo.v11.i10.804. World J Gastrointest Oncol. 2019. PMID: 31662821 Free PMC article. Review.
-
Rangel LP, Ferretti GDS, Costa CL, Andrade SMMV, Carvalho RS, Costa DCF, Silva JL. Rangel LP, et al. J Biol Chem. 2019 Mar 8;294(10):3670-3682. doi: 10.1074/jbc.RA118.004671. Epub 2019 Jan 2. J Biol Chem. 2019. PMID: 30602570 Free PMC article.
-
Hoshino I, Takahashi M, Akutsu Y, Murakami K, Matsumoto Y, Suito H, Sekino N, Komatsu A, Iida K, Suzuki T, Inoue I, Ishige F, Iwatate Y, Matsubara H. Hoshino I, et al. Oncol Lett. 2019 Jul;18(1):872-881. doi: 10.3892/ol.2019.10350. Epub 2019 May 13. Oncol Lett. 2019. PMID: 31289565 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous